Please login to the form below

Not currently logged in
Email:
Password:

Oxford Cancer Biomarkers

This page shows the latest Oxford Cancer Biomarkers news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca expands personalised drug partnership with Horizon

AstraZeneca expands personalised drug partnership with Horizon

AstraZeneca expands personalised drug partnership with Horizon. Companies will research drug targets for targeted cancer treatments. ... Other recent oncology agreements made by AZ since Soriot's appointment include a research alliance with Cancer

Latest news

  • FDA to review AZ's fish oil drug Epanova FDA to review AZ's fish oil drug Epanova

    These other deals include the acquisition of cancer specialist Amplimmune and US biotech AlphaCore Pharma; the acquisition of a drug developed by FibroGen for anaemia associated with chronic kidney disease; and ... AZ has also entered research

  • AZ adds to pipeline again with Amplimmune buy AZ adds to pipeline again with Amplimmune buy

    It will allow us to strengthen our arsenal of potential cancer therapies," he added. ... Added to that haul have been collaborations with Moderna Therapeutics, the Karolinska Institutet and Oxford Cancer Biomarkers, as well as a $200m licence agreement

  • AZ inks $815m deal for FibroGen anaemia drug AZ inks $815m deal for FibroGen anaemia drug

    Most recently the firm snapped up respiratory specialist Pearl Therapeutics in a deal valued at up to $1.15bn, having previously forged collaborations with Moderna Therapeutics, the Karolinska Institutet and Oxford ... Cancer Biomarkers, as well as a

  • AstraZeneca and NGM form diabetes/ obesity partnership AstraZeneca and NGM form diabetes/ obesity partnership

    These deals include the acquisition of Pearl Therapuetics, Omthera Pharmaceuticals and AlphaCore Pharma, as well as collaboration agreements with Moderna Therapuetics and Oxford Cancer Biomarkers.

  • AstraZeneca boosts R&D prospects with Pearl acquisition AstraZeneca boosts R&D prospects with Pearl acquisition

    These deals include collaboration agreements with Moderna Therapeutics, the Karolinska Institutet and Oxford Cancer Biomarkers, as well as a licence agreement with Bind Therapeutics and the purchase of US biotechs AlphaCore

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    2 trials for NSCLC, and tremelimumab, an anti-CTLA4 MAb in phase 2 for the rare cancer mesothelioma. “ ... Critical to that thinking is keeping track of the latest developments in technology and working with companies, such as Oxford Cancer Biomarkers,

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Rainmaker Healthcare Communications

Rainmaker is an independent, award-winning communications agency with offices in London and Atlanta. Our experience across pharmaceuticals, generics, OTC, medical...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics